Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX001 Drug-Drug Interaction Study with Itraconazole and Rifampin
NCT04166669Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosmanogepix in fungal infection (2 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoints: Area under the plasma concentration-time curve at 6 weeks, Maximum observed plasma concentration at 6 weeks and 4 more. Started Nov 2019; status: completed.
02
Drugs
fosmanogepix
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT04166669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166669.